Hematopoietic Cell Transplantation–Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation Mariano Berro,

Slides:

Advertisements

Similar presentations

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Advertisements

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Admission of Hematopoietic Cell Transplantation Patients to the Intensive Care Unit at the Pontificia Universidad Católica de Chile Hospital Karen Escobar,

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.

Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic.

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell.

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents Andreas Kyvernitakis,

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors Auayporn Nademanee,

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,

Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Anuj Mahindra, Brian Bolwell, Ronald.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation Pere Barba, Jose Luis Piñana, David.

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Costs and Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Children Are Predictable Susanne Matthes-Martin, Ulrike Pötschger, Ronald Barr,

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Gerard Socié, K. Scott Baker, Smita Bhatia

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Validation of the Hematopoietic Cell Transplantation–Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation Muthu Veeraputhiran,

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving.

Blood and Marrow Transplant Handbook

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count.

Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Mark A. Fiala, Joseph D. Finney, Keith.

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome Peggy A. Wu,

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Treatment versus Transplant for Challenging Hematologic Disorders

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

Hematopoietic Cell Transplantation–Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation Mariano Berro, Jorge A. Arbelbide, Maria M. Rivas, Ana Lisa Basquiera, Gonzalo Ferini, Adriana Vitriu, Cecilia Foncuberta, Nicolas Fernandez Escobar, Alejandro Requejo, Vera Milovic, Sebastian Yantorno, Milagros Szelagoswki, Juliana Martinez Rolon, Gonzalo Bentolila, Juan Jose Garcia, Pablo Garcia, Gaston Caeiro, Martin Castro, Gregorio Jaimovich, Silvina Palmer, Jose I. Trucco, Lucia A. Bet, Bronwen E. Shaw, Gustavo D. Kusminsky Biology of Blood and Marrow Transplantation Volume 23, Issue 10, Pages 1646-1650 (October 2017) DOI: 10.1016/j.bbmt.2017.06.014 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 NRM according to HCT-CI score in the full cohort. High Risk HCT-CI patients had a significantly higher NRM compared to Intermediate and Low Risk patients. Biology of Blood and Marrow Transplantation 2017 23, 1646-1650DOI: (10.1016/j.bbmt.2017.06.014) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 NRM according to HCT-CI score in lymphoma patients. High Risk HCT-CI patients had a significantly higher NRM compared to Intermediate and Low Risk patients. Biology of Blood and Marrow Transplantation 2017 23, 1646-1650DOI: (10.1016/j.bbmt.2017.06.014) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 OS according to HCT-CI score in lymphoma patients. High Risk HCT-CI patients had a significantly lower OS compared to Intermediate/Low Risk patients. Biology of Blood and Marrow Transplantation 2017 23, 1646-1650DOI: (10.1016/j.bbmt.2017.06.014) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions